Monday, November 28, 2011

Fountain of Youth?

Fountain of Youth?

Forget the eye cream and aerobics classes – new research out of Dr. Darren Baker’s lab at the Mayo Clinic suggests that a better understanding of the molecular mechanisms of aging may one day result in treatments that intervene in the root causes of age-related degeneration, rather than simply treat the symptoms.

Dr. Baker’s research focuses on a protein known as p16INK4A. This is a protein that is produced when cells approach the upper limit of the number of times that they can divide – a number known as the Hayflick limit, thought to be an anti-cancer mechanism in cells but also associated with cell senescence – aging and death. The challenge has been to figure out a way around this Hayflick limit without inducing cancer.

The Baker lab may have found such a workaround. Studying a type of mouse born with progeria – a condition that causes the mice to age much more rapidly than normal – Dr. Baker’s group observed that not only do rapidly aging cells deteriorate, but that they also seem to have adverse affects on other, healthy cells nearby. This led them to hypothesize that if they could somehow selectively kill the most rapidly aging cells, the mice would get two benefits for the price of one.

Since the most rapidly aging cells are also the first cells to start producing p16INK4A, this protein could also serve as a targeting mechanism for the selective destruction of rapidly aging cells. Dr. Baker’s team genetically engineered a strain of progeriatric mice that would produce a second protein whenever the production of p16INK4A increased. This second protein is harmless, but is converted into a toxic form when the mice are administered an activating drug. This toxic form results in the death of the cells that contain it – but not the surrounding healthy cells.
The results of this experiment, published last month in Nature, were nothing short of astounding. The engineered mice exposed to the activating drug showed markedly fewer signs of aging – less muscle wasting, fewer cataracts, better performance on treadmill tests. These results offer the tantalizing possibility that there may in fact someday be a silver bullet to selectively destroy aging cells in humans, leaving behind stronger, healthy cells and tissues.

posted by BioTech Primer at 12:48 PM

3 Comments:

Anonymous Melody said...

Hello,

My name is Melody Wilding and I’ve been following your blog posts about investing in biotech. I really enjoy your perspective on innovation in the field. These are important issues facing the development of healthcare, so the information that your blog provides is extremely important and I thank you for it.

I would like to inform you about a very important event called OneMedForum. For five years, the OneMedForum Emerging Company Finance Conference hosted by OneMedPlace has gathered emerging growth companies from the US and abroad, drawing over 1000 delegates including leading institutional investors and business development executives.

The 5th Annual OneMedForum will be held on January 9 – 12, 2012 at the Sir Francis Drake Hotel in San Francisco. The Forum has grown in size and stature to become one of the most important events shaping the future of health and medicine globally.

Check out this year’s highlights, including our China Forum and Hot Areas of Investment panels at www.onemedplace.com/forum.

We welcome the opportunity to collaborate with you and spread the word about OneMedForum your readers. I would like to ask you to pass along to your readers information about this event, since it could be so helpful to them. Our forum is the perfect way to align your blog as a supporter the future of health and medicine.

We would love to work with to best suit your blog’s needs, such as a recent press release or website banner. In exchange, we would be happy to feature and link to your blog on our News page: http://www.onemedplace.com/blog/

Let us know what you think would work best. We're excited to be working with you.

If you have any questions, just call me at 212-734-1008 or email me at mwilding@onemedplace.com.

Best regards,

Melody J. Wilding
Communications Manager
OneMedPlace
mwilding@onemedplace.com
212-734-1008

December 1, 2011 9:44 AM  
Anonymous Anonymous said...

BSPM is currently followed by 2 analysts. Both give the stock a positive rating. The average price target is 8.07, which implies 1,222.13% upside from current price.

December 10, 2011 1:42 PM  
Anonymous Chiropractor Melbourne said...

Good research. Stay focused and you'll achieve your goal.

January 6, 2012 10:08 AM  

Post a Comment

Subscribe to Post Comments [Atom]

<< Home

About Me

Name: BioTech Primer

At Biotech Primer our goal is to enable non-scientists to understand the fundamental science that drives the Biotech/Pharma Industry. Here we'll discuss new discoveries and breakthroughs that will impact the Industry now and in the future.

View my complete profile

Previous Posts

  • CHO Cells Explained
  • Regulation of Biosimilars
  • BioSimilars vs. Generic Drugs: What’s In a Word?
  • Personalized Medicine: Seasonal Variation?
  • Good News for Stem Cell Researchers
  • Nanotech Device for Monitoring Tumor Progression
  • miRNA as a Diagnostic
  • Biofuels From Proteins?
  • Obscure Syndrome, Cancer Cure?
  • Bacteria: The Secret to Happiness?

Powered by Blogger

Subscribe to
Posts [Atom]